Skip to main content
Top
Published in: Infection 3/2014

01-06-2014 | Brief Report

Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia

Authors: B. Lakatos, B. Jakopp, A. Widmer, R. Frei, H. Pargger, L. Elzi, M. Battegay

Published in: Infection | Issue 3/2014

Login to get access

Abstract

Objective

The goal of this study was to retrospectively collect data about treatment outcomes in patients diagnosed with Stenotrophomonas maltophilia bacteraemia over a period of 20 years and evaluate these data with respect to the efficacy of treatment options.

Methods

The setting was a 700-bed tertiary care hospital in a large urban area. Hospital databases and medical records provided information about episodes of S. maltophilia, patient characteristics and treatment outcomes. Patients with at least one positive blood culture for S. maltophilia were included in the study. Data were analysed with respect to clinical improvement and mortality ≤30 days after the onset of infection. We compared patient characteristics, laboratory values and treatments by using the Chi-square or Fisher’s exact tests and the Mann–Whitney test.

Results

We investigated 27 patients with S. maltophilia bacteraemia. The focus of infection was a central venous catheter in 18 (67 %) cases. The 30-day mortality rate was 11 %. All patients who were treated with an antibiotic that was effective in vitro against the pathogen recovered clinically and survived ≥30 days after the onset of infection. The most frequently used antibiotic was trimethoprim–sulfamethoxazole administered alone or in combination with a fluoroquinolone.

Conclusions

Despite the fact that S. maltophilia is resistant to multiple antibiotics, the prognosis for patients with S. maltophilia bacteraemia is good when they are treated with antibiotics that are effective against this pathogen in vitro.
Literature
1.
go back to reference Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9:312–23.PubMedCrossRef Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9:312–23.PubMedCrossRef
2.
go back to reference Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26:229–37.PubMedCrossRef Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26:229–37.PubMedCrossRef
3.
go back to reference Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim–sulfamethoxazole in the ambulatory setting. Curr Drug Saf. 2013;8:114–9.PubMedCrossRef Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim–sulfamethoxazole in the ambulatory setting. Curr Drug Saf. 2013;8:114–9.PubMedCrossRef
4.
go back to reference Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38:211–5.PubMedCrossRef Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38:211–5.PubMedCrossRef
5.
go back to reference Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81:114–8.PubMedCrossRef Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81:114–8.PubMedCrossRef
6.
go back to reference Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22:508–12.PubMedCrossRef Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22:508–12.PubMedCrossRef
7.
go back to reference Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34:1653–6.PubMedCrossRef Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34:1653–6.PubMedCrossRef
8.
go back to reference Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32.PubMedCrossRef Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32.PubMedCrossRef
9.
go back to reference Carroll KC, Cohen S, Nelson R, Campbell DM, Claridge JD, Garrison MW, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 1998;32:229–35.PubMedCrossRef Carroll KC, Cohen S, Nelson R, Campbell DM, Claridge JD, Garrison MW, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 1998;32:229–35.PubMedCrossRef
10.
go back to reference Fihman V, Le Monnier A, Corvec S, Jaureguy F, Tankovic J, Jacquier H, et al. Stenotrophomonas maltophilia—the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect. 2012;64:391–8.PubMedCrossRef Fihman V, Le Monnier A, Corvec S, Jaureguy F, Tankovic J, Jacquier H, et al. Stenotrophomonas maltophilia—the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect. 2012;64:391–8.PubMedCrossRef
11.
go back to reference Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997–1999). Clin Infect Dis. 2001;32:S104–13.PubMedCrossRef Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997–1999). Clin Infect Dis. 2001;32:S104–13.PubMedCrossRef
Metadata
Title
Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia
Authors
B. Lakatos
B. Jakopp
A. Widmer
R. Frei
H. Pargger
L. Elzi
M. Battegay
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 3/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0607-3

Other articles of this Issue 3/2014

Infection 3/2014 Go to the issue